Array Biopharma Inc.

Eugene Tarlton

Ellen Ruth Laird

Adam Wade Cook

Li Ren

David A Moreno

Andrew T Metcalf

Erik James Hicken

Bradley Jon Newhouse

Spencer Phillip Pajk

Dean Russell Kahn

Patrick Michael Barbour

Brett Joseph Prigaro

Katie Keaton Brown

Qian Zhao

Laurence Edward Burgess

Timothy S Kercher

Anthony D Piscopio

Mark Laurence Boys

Robert D Groneberg

Darren Martin Harvey

Lily Huang

Christopher F Kraser

Jack (ChanKou) Hwang

Andrew Terrance Metcalf

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R, R, R, R, R, R, R, Xand Xhave the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases

Disclosed is a process for selectively reducing a nitrile containing organic compound that also contains a sulfone moiety, the nitrile being reduced to a primary amine.

Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones

Growing community of inventors

Lafayette, CO, United States of America

Eugene Tarlton